Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros

Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Clin Nephrol ; 64(4): 320-2, 2005 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-16240906

RESUMEN

AIMS: Sevelamer hydrochloride is a polymer containing multiple amines (40% amine hydrochloride) separated by one carbon from the polymer backbone, and it is not absorbed by the intestine. These amines are partially protonated and interact with phosphate molecules through ionic and hydrogen bonding, therefore reducing phosphate absorption and lowering serum phosphate concentration. Alterations of gastric pH, in particular excessive alkalinization, could interfere with sevelamer phosphate binding capacity. CASE HISTORY: A 30-year-old dialysis patient affected by secondary hyperparathyroidism started sevelamer treatment, 4.8 g/day, with a basal serum phosphate of 6.9 mg/dl. The patient was also treated with omeprazole (20 mg/day) because of chronic gastritis. Phosphate levels normalized (4.2 mg/dl), but after four months of follow-up serum phosphate unexpectedly increased to 7.2 mg/dl. We found out that in the same period she had autonomously increased the dosage of omeprazole to 80 mg/day, due to worsening of dyspepsia. Gastric pH measurement showed a median level of 4.1, rather than the normal values of 1 - 2, indicating excessive pharmacological alkalinization. When omeprazole was reduced to the correct dose of 20 mg/day, we observed a rapid decrease of phosphate levels. CONCLUSION: This case report highlights the influence of gastric pH on sevelamer phosphate binding capacity. The high dose of omeprazole and the consequent excessive increase in gastric pH was probably responsible for a decreased phosphate binding capacity of sevelamer. When patients taking appropriate doses of sevelamer do not respond to treatment, a potential interaction with drugs determining an increase of gastric pH should be considered.


Asunto(s)
Antiulcerosos/uso terapéutico , Ácido Gástrico/metabolismo , Gastritis/tratamiento farmacológico , Hiperparatiroidismo Secundario/tratamiento farmacológico , Omeprazol/uso terapéutico , Poliaminas/uso terapéutico , Adulto , Antiulcerosos/administración & dosificación , Antiulcerosos/farmacocinética , Enfermedad Crónica , Relación Dosis-Respuesta a Droga , Interacciones Farmacológicas , Femenino , Estudios de Seguimiento , Gastritis/complicaciones , Gastritis/metabolismo , Humanos , Concentración de Iones de Hidrógeno/efectos de los fármacos , Hiperparatiroidismo Secundario/complicaciones , Hiperparatiroidismo Secundario/metabolismo , Omeprazol/administración & dosificación , Omeprazol/farmacocinética , Fosfatos/sangre , Poliaminas/administración & dosificación , Poliaminas/farmacocinética , Sevelamer
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA